RhumbLine Advisers
MBX

RhumbLine Advisers’s MBX Biosciences MBX Stock Holding History

RhumbLine Advisers’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.05M Buy
37,196
+3,325
+10% +$116K ﹤0.01% 1922
2026
Q1 		$1.01M Buy
33,871
+451
+1% +$15.3K ﹤0.01% 2193
2025
Q4 		$1.05M Buy
33,420
+11,599
+53% +$281K ﹤0.01% 2192
2025
Q3 		$382K Sell
21,821
-1,841
-8% -$24.6K ﹤0.01% 2864
2025
Q2 		$270K Buy
23,662
+14,950
+172% +$152K ﹤0.01% 3058
2025
Q1 		$64.3K Sell
8,712
-760
-8% -$8.04K ﹤0.01% 3515
2024
Q4 		$175K Buy
+9,472
New +$202K ﹤0.01% 3265

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

RhumbLine Advisers's MBX Position: Q2 2026 in Review

RhumbLine Advisers increased its MBX Biosciences (MBX) stake by 9.8% in Q2 2026, buying an estimated $116K and bringing the position to 37,196 shares worth $2.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1922.

RhumbLine Advisers first reported a position in MBX in Q4 2024 and has held it in 7 quarters since. 173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • RhumbLine Advisers held 37,196 shares of MBX Biosciences worth $2.05M as of Q2 2026.
  • RhumbLine Advisers bought 3,325 MBX Biosciences shares in Q2 2026, an estimated $116K.
  • MBX Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1922 holding.
  • RhumbLine Advisers first reported a position in MBX Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.